EPI Health Signs Agreement With SMG Pharmaceuticals to Promote BENSAL HP®

News provided by

Jul 26, 2017, 18:45 ET

CHARLESTON, S.C., July 26, 2017 /PRNewswire/ -- EPI Health LLC ("EPIH" or the "Company"), a specialty pharmaceutical company wholly owned by EPI Group LLC, announced an agreement with SMG Pharmaceuticals Inc. ("SMG") to market and sell BENSAL HP^®. EPIH relaunched the sale of Bensal HP on July 12 with a full-scale marketing effort supported by EPIH's team of dermatologic sales professionals. The product will be promoted to prescribing physicians across the country.

"We are excited to add BENSAL HP to the EPIH product portfolio," said Ron Owens, president of EPI Health. "BENSAL HP provides us with an excellent opportunity to leverage our greatest asset – our team of professional sales men and women. This drug represents a significant step in our commitment to provide effective, innovative dermatological solutions through prescription products. We are actively seeking innovative product candidates that will complement our therapeutic expertise, strengthen our portfolio, and deliver novel products to health care professionals and patients in the United States."

BENSAL HP is an external, topical treatment for excoriated skin vulnerable to infection and slow to heal. The treatment provides protection with a broad-spectrum antimicrobial, promotes faster healing and reduces inflammation. It is particularly effective with inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyoderma.

EPI Health is pursuing an aggressive acquisition strategy that builds on its commitment to provide effective, innovative dermatological solutions through prescription products. The carefully considered acquisition focus will further diversify the Company to provide consistent profitability in a wide range of economic conditions. The Company is poised to take advantage of compelling investment opportunities to benefit business partners for generations to come.

Those interested in partnering with EPI Health regarding product licensing and commercialization opportunities may contact Ron Owens by email at [email protected] or by phone at (843) 937-4786.

For media inquiries, please contact Jesse Darland by email at [email protected] or by phone at (773) 250-5350.

For more information on the Company, please visit EPI Health's website at www.epihealth.com

About EPI Health and EPI Group

Headquartered in Charleston, South Carolina, EPI Health is a specialty pharmaceutical company focused on acquiring, developing and marketing prescription medical dermatological products. EPI Health is a wholly owned subsidiary of EPI Group.

EPI Group is a privately held company headquartered in Charleston, South Carolina with over 2,000 employees. The Company's diverse portfolio includes: Evening Post Publishing, which has seventeen publications in the state of South Carolina including the 2015 Pulitzer Prize-winning Post and Courier; Cordillera Communications, a network of 11 broadcast television stations covering 2.3 million households; Heart of Hospice, a hospice provider operating multiple locations across Louisiana, Mississippi and Arkansas; and Clear Night Group, a digital marketing agency based in Minnesota.

About SMG Pharmaceuticals

SMG Pharmaceuticals is a specialty biotechnology company. Located in Summerton, South Carolina, the firm develops new products that provide innovative treatments for patients with skin diseases and conditions.

Related Images

Related Links

SOURCE EPI Health LLC